Skip to main content
Resverlogix Corp. logo

Resverlogix Corp. — Investor Relations & Filings

Ticker · RVX ISIN · CA76128M1086 LEI · 529900VI46SAPCOSH758 TSX Real estate activities
Open in API
Filings indexed 195 across all filing types
Latest filing 2020-11-21 Regulatory Filings
Country CA Canada
Listing TSX RVX

About Resverlogix Corp.

https://www.resverlogix.com/

Resverlogix Corp. is a late-stage clinical biotechnology company specializing in the development of epigenetic therapies for chronic illnesses. The company's core scientific focus involves regulating the expression of disease-causing genes. Its lead drug candidate is Apabetalone, a small molecule inhibitor currently being advanced through clinical programs, including the BETonMACE trial. Apabetalone is primarily targeted toward treating cardiovascular diseases and complications associated with diabetes mellitus. Resverlogix aims to provide novel science and value-based health solutions to key stakeholders, including pharmaceutical companies, physicians, and health payer groups.

Recent filings

Filing Released Lang Actions
Form of proxy - English.pdf
Regulatory Filings
2020-11-21 English
Notice of meeting - English.pdf
AGM Information Classification · 95% confidence The document is a Notice of Annual and Special Meeting for Resverlogix Corp. It outlines the agenda for the meeting, including receiving audited financial statements, electing directors, appointing auditors, and other shareholder matters. It also provides logistical details about the meeting date, location, and webcast information. The document does not contain the actual financial statements or detailed reports but serves as a formal notice to shareholders about the upcoming meeting and the matters to be discussed and voted on. This fits the definition of AGM Information (AGM-R), which includes presentations and materials shared during the Annual General Meeting. The document length is under 5,000 characters and is clearly a notice rather than a full report or financial statement.
2020-11-21 English
Management information circular - English.pdf
Regulatory Filings
2020-11-21 English
Report of exempt distribution excluding schedule 1 of Form 5.pdf
Regulatory Filings Classification · 100% confidence The document text contains only a placeholder message indicating that the proper contents of the document are not displayed and suggests upgrading Adobe Reader. There is no substantive content related to any financial report, announcement, or filing. The document length is very short (692 characters) and does not contain any financial data, regulatory references, or report titles. Therefore, it does not fit any specific filing category and should be classified as a Regulatory Filing (RNS) as a fallback for miscellaneous or non-informative filings.
2020-11-13 English
News release - English.pdf
Regulatory Filings Classification · 95% confidence The document is a press release announcing the publication of a scientific article in a peer-reviewed journal and upcoming presentations at a scientific conference. It discusses research findings related to the company's drug apabetalone and its effects on immune cells in diabetic and cardiovascular disease patients. There are no financial statements, regulatory filings, or detailed financial data. The document is informational and promotional about research and upcoming events, not a financial report or regulatory filing. It does not fit into categories like Annual Report, Interim Report, Earnings Release, or Regulatory Filings. It is also not a presentation or investor presentation but rather a news release about a publication and event. Given the content and nature, the best fitting category is Regulatory Filings (RNS) as a general announcement that does not fit other specific categories.
2020-11-12 English
News release - English.pdf
Regulatory Filings Classification · 95% confidence The document is a press release announcing the filing of new intellectual property (provisional patent applications) related to clinical trial results (BETonMACE Phase 3 trial) showing improvements in renal and glucose control markers. It discusses clinical findings, patent filings, and strategic implications for the company’s drug apabetalone. There are no financial statements, regulatory certifications, voting results, or management changes. The content is primarily an announcement of new intellectual property filings and clinical trial results, not a financial report, earnings release, or regulatory filing. It is not a report publication announcement since it does not mention the release of a formal report but rather the filing of patents and clinical findings. This fits best under Regulatory Filings (RNS) as a general regulatory announcement and corporate update that does not fit other specific categories.
2020-11-02 English

Browse filings by year

7 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.